Cat Allergy Vaccine Launches Human Clinical Trial

While there is currently no cure for cat allergy, a prevalent, life-long condition, an innovative therapeutic vaccine for humans has begun clinical trials.

Angany Inc. today announced that it has received clearance from U.K.'s Medicines and Healthcare Products Regulatory Agency for the first clinical study to be conducted on its vaccine candidate ANG-101 to treat human allergy to cats.

ANG-101 is a therapeutic vaccine that provides a disruptive disease-modifying approach for treating cat allergy.

Derived from its proprietary eBioparticle-Potentiated Immunotherapy™ technology, ANG-101 active immunotherapeutic ingredient is a unique 140 nm enveloped bioparticle (eBioparticle™) that mimics a virus in shape and size with its surface covered with thousands of copies of cat major allergen Fel d 1.

This clinical study is a first-in-human, open-label, and single-site evaluation of the new vaccine's safety, allergenicity, and immunogenicity in adult patients allergic to cat dander.

This early-stage clinical trial will be conducted under the guidance of Professor Stephen Durham and Dr Guy Scadding, two leading clinical allergy experts from Imperial College London.

Professor Durham commented in a press release on October 5, 2023, "The potential treatment of cat allergy using an auto-adjuvanted vector builds upon its known ability to induce strong allergen-specific IgG antibody responses, as observed in animal models."

Unlike prophylactic vaccines, Angany’s therapeutic vaccines are a new generation of immunotherapy biologics used to treat established pathologies.

They are meant to restore or boost natural immune mechanisms and create sustainable immune protection and vigilance.

Human allergies to cats and dogs affect 10 to 20% of the world’s population, says the Asthma and Allergy Foundation of America.

When you have a pet allergy, you are not allergic to the pet’s hair, fur, or feathers but to the protein found in the pet’s dander, saliva, and urine.